Free Trial
NASDAQ:PHAT

Phathom Pharmaceuticals (PHAT) Stock Price, News & Analysis

Phathom Pharmaceuticals logo
$8.78 -0.31 (-3.41%)
(As of 11/15/2024 ET)

About Phathom Pharmaceuticals Stock (NASDAQ:PHAT)

Key Stats

Today's Range
$8.54
$9.30
50-Day Range
$8.78
$19.50
52-Week Range
$6.07
$19.71
Volume
2.16 million shs
Average Volume
1.84 million shs
Market Capitalization
$600.38 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$22.50
Consensus Rating
Moderate Buy

Company Overview

Phathom Pharmaceuticals, Inc., biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada for an investigational potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. The company was incorporated in 2018 and is headquartered in Florham Park, New Jersey.

Phathom Pharmaceuticals Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
56th Percentile Overall Score

PHAT MarketRank™: 

Phathom Pharmaceuticals scored higher than 56% of companies evaluated by MarketBeat, and ranked 545th out of 970 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Phathom Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on 3 buy ratings, 1 hold rating, and no sell ratings.

  • Amount of Analyst Coverage

    Phathom Pharmaceuticals has only been the subject of 1 research reports in the past 90 days.

  • Read more about Phathom Pharmaceuticals' stock forecast and price target.
  • Earnings Growth

    Earnings for Phathom Pharmaceuticals are expected to grow in the coming year, from ($6.03) to ($4.58) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Phathom Pharmaceuticals is -1.54, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Phathom Pharmaceuticals is -1.54, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Read more about Phathom Pharmaceuticals' valuation and earnings.
  • Percentage of Shares Shorted

    25.52% of the outstanding shares of Phathom Pharmaceuticals have been sold short.
  • Short Interest Ratio / Days to Cover

    Phathom Pharmaceuticals has a short interest ratio ("days to cover") of 16.3, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Phathom Pharmaceuticals has recently decreased by 0.63%, indicating that investor sentiment is improving.
  • Dividend Yield

    Phathom Pharmaceuticals does not currently pay a dividend.

  • Dividend Growth

    Phathom Pharmaceuticals does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    25.52% of the outstanding shares of Phathom Pharmaceuticals have been sold short.
  • Short Interest Ratio / Days to Cover

    Phathom Pharmaceuticals has a short interest ratio ("days to cover") of 16.3, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Phathom Pharmaceuticals has recently decreased by 0.63%, indicating that investor sentiment is improving.
  • News Sentiment

    Phathom Pharmaceuticals has a news sentiment score of 0.77. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.56 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 4 news articles for Phathom Pharmaceuticals this week, compared to 3 articles on an average week.
  • Search Interest

    5 people have searched for PHAT on MarketBeat in the last 30 days. This is an increase of 400% compared to the previous 30 days.
  • MarketBeat Follows

    Only 2 people have added Phathom Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of -33% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Phathom Pharmaceuticals insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    24.10% of the stock of Phathom Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    99.01% of the stock of Phathom Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Phathom Pharmaceuticals' insider trading history.
Receive PHAT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Phathom Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

PHAT Stock News Headlines

Trump’s Back, but DC’s Coming for Your Money!
Trump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy with a heavy hand—building up infrastructure, slapping tariffs on imports, and going all-in on U.S. jobs. But here's the kicker: while Trump's focused on making America stronger, the Washington elite is ready to fight back…
Phathom Pharmaceuticals (PHAT) Receives a Buy from Stifel Nicolaus
Phathom Pharmaceuticals Reports Significant Revenue Growth
See More Headlines

PHAT Stock Analysis - Frequently Asked Questions

Phathom Pharmaceuticals' stock was trading at $9.13 on January 1st, 2024. Since then, PHAT stock has decreased by 3.8% and is now trading at $8.78.
View the best growth stocks for 2024 here
.

Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) issued its quarterly earnings data on Thursday, March, 7th. The company reported ($0.80) earnings per share for the quarter, topping analysts' consensus estimates of ($0.92) by $0.12. The company had revenue of $0.68 million for the quarter, compared to analyst estimates of $0.93 million.

Phathom Pharmaceuticals (PHAT) raised $150 million in an initial public offering (IPO) on Friday, October 25th 2019. The company issued 7,900,000 shares at a price of $18.00-$20.00 per share. Goldman Sachs, Jefferies and Evercore ISI acted as the underwriters for the IPO and Needham & Company was co-manager.

Top institutional investors of Phathom Pharmaceuticals include Jennison Associates LLC (9.84%), Portolan Capital Management LLC (2.49%), Checkpoint Capital L.P. (2.20%) and FMR LLC (1.91%). Insiders that own company stock include Pharmaceutical Co Ltd Takeda, Terrie Curran, Azmi Nabulsi and Asit Parikh.
View institutional ownership trends
.

Shares of PHAT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that Phathom Pharmaceuticals investors own include American Water Works (AWK), The RMR Group (RMR), DiamondRock Hospitality (DRH), Waste Connections (WCN), AUO (AUOTY), iShares Micro-Cap ETF (IWC) and Voyager Therapeutics (VYGR).

Company Calendar

Last Earnings
3/07/2024
Today
11/17/2024
Fiscal Year End
12/31/2024
Next Earnings (Estimated)
3/06/2025

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:PHAT
Fax
N/A
Employees
110
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$22.50
High Stock Price Target
$28.00
Low Stock Price Target
$12.00
Potential Upside/Downside
+156.3%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.75
Research Coverage
4 Analysts

Profitability

Net Income
$-201,590,000.00
Net Margins
-1,292.14%
Pretax Margin
-1,292.14%

Debt

Sales & Book Value

Annual Sales
$680,000.00
Book Value
($2.74) per share

Miscellaneous

Free Float
51,898,000
Market Cap
$600.38 million
Optionable
Optionable
Beta
0.72
(Almost)  Everything You Need To Know About The EV Market Cover

Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.

Get This Free Report

This page (NASDAQ:PHAT) was last updated on 11/17/2024 by MarketBeat.com Staff
From Our Partners